Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 4Depression 4Head and Neck Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Fatigue 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Sleep Wake Disorders 1Recurrence 1Radiation Fibrosis Syndrome 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Acceptance of Health Care 1Pain 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Calculi 1Inflammatory Breast Neoplasms 1Immune Checkpoint Inhibitor-Induced Dermatitis 1Health Education 1Constriction, Pathologic 1

Interventions

Rituximab 40Cyclophosphamide 36Prednisone 24Doxorubicin 23Magnetic Resonance Spectroscopy 20Vincristine 19Gemcitabine 18Specimen Handling 17Lenalidomide 17Biopsy 15Oxaliplatin 14polatuzumab vedotin 13obinutuzumab 11glofitamab 11ibrutinib 10fludarabine 8Etoposide 8Dexamethasone 8CT-P10 8prednylidene 7deltacortene 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6pembrolizumab 6Prednisolone 6fludarabine phosphate 5acalabrutinib 5R-CHOP protocol 5Cyclosporine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Therapeutics × 90 days × Clear all
NCT07621406 2026-06-02

Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Active not recruiting
25 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡